Released Aug 10, 2022, after the close
10-Q filed Aug 10, 2022, 41 days after period end · 0000950170-22-016443
Q2 2022 · 10-Q
Revenue$896.00K$896.00K −57.5% vs Q2 2021+262.8% vs Q1 2022
Net Income-$28.70M-$28.70M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.87-$0.87 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$26,080,000N/M
Operating Cash Flowderived-$23,033,000N/M
Margins · derived
Operating margin-2910.7%−2030.3 pt vs Q2 2021
Net margin-3203.1%−2319.9 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $896.00K | $2.11M | $51.00K | $67.00K |
| Net Income | -$28.70M | -$18.60M | -$17.50M | -$13.20M |
| EPS Diluted | -$0.87 | -$0.63 | -$0.85 | -$0.74 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR